

10/10/03
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Shalini Sharma Atty. Ref.: 18015-D4
Appl. No.: Not Yet Assigned Group Art Unit: 1624
Filed: Herewith Examiner: Sudhaker B. Patel
For: COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

* * * * *

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

→ MW PS.

Mr. Cheek

11/10/03
1624

OK
Reid
10/10/03

Sir:
COMMUNICATION REQUESTING DELETION OF INVENTOR
UNDER 37 CFR 1.63(d)(2)

This is a request for deletion of one of the inventors named on the Declaration in accordance with the provisions of 37 CFR 1.63(d)(2). Reid W. von Borstel is not an inventor of the subject matter being claimed in the divisional patent application submitted herewith. The inventor of the subject matter being claimed is Shalini Sharma.

Respectfully submitted,

Lewis J. Kreisler
Lewis J. Kreisler
Reg. No. 38522
Attorney for Applicant(s)

930 Clopper Road
Gaithersburg, MD 20878
Phone: (240) 631-2500 x3276
Facsimile: (240) 683-3794

6/18/04

Dkt. 18015-D4

→ Mr PS
P. Cheek B. T. T. P. 6/24

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

5 CROSS-REFERENCE TO PRIOR APPLICATIONS

This is a divisional of U.S. Patent Application No. 10/167,839, filed June 12, 2002, the content of which is incorporated herein by reference. This application claims the benefit of U.S. Provisional Patent Application No. 60/297,282, filed June 12, 2001, the content of which is incorporated herein by reference.

BACKGROUND OF THE INVENTION

Diabetes mellitus is a major cause of morbidity and mortality. Chronically elevated blood glucose leads to debilitating complications: nephropathy, often necessitating dialysis or renal transplant; peripheral neuropathy; retinopathy leading to blindness; ulceration of the legs and feet, leading to amputation; fatty liver disease, sometimes progressing to cirrhosis; and vulnerability to coronary artery disease and myocardial infarction.

There are two primary types of diabetes. Type I, or insulin-dependent diabetes mellitus (IDDM) is due to autoimmune destruction of insulin-producing beta cells in the pancreatic islets. The onset of this disease is usually in childhood or adolescence. Treatment consists primarily of multiple daily injections of insulin, combined with frequent testing of blood glucose levels to guide adjustment of insulin doses, because excess insulin can cause hypoglycemia and consequent impairment of brain and other functions.

Type II, or noninsulin-dependent diabetes mellitus (NIDDM) typically develops in adulthood. NIDDM is associated with resistance of glucose-utilizing tissues like adipose tissue, muscle, and liver, to the actions of insulin. Initially, the pancreatic islet beta cells compensate by secreting excess insulin. Eventual islet failure results in decompensation and chronic hyperglycemia. Conversely, moderate islet insufficiency can precede or coincide with peripheral insulin resistance. There are several classes of drugs that are